Logo

PTIX

Protagenic Therapeutics, Inc.

PTIX

Protagenic Therapeutics, Inc. • NASDAQ
$2.13 ▼ -4.48% (-0.10)
Market Cap $4.11 M
52w High $14.28
52w Low $1.83
Dividend Yield 0%
P/E -0.16
Volume 86.35K
Outstanding Shares 1.93M

Income Statement

Period Revenue Operating Expense Net Income Net Profit Margin Earnings Per Share EBITDA
Q3-2025 $0 $1.114M ▼ $-869.496K ▲ 0% $-0.47 ▲ $-1.114M ▲
Q2-2025 $0 $2.332M ▲ $-5.058M ▼ 0% $-1.37 ▲ $-4.806M ▼
Q1-2025 $0 ▲ $1.448M ▼ $-1.44M ▲ 0% ▼ $-2.75 ▼ $-1.436M ▲
Q4-2024 $-25.143K ▼ $1.643M ▲ $-1.554M ▼ 6.181K% ▲ $-0.24 ▼ $-1.541M ▼
Q3-2024 $0 $652.066K $-641K 0% $-0.14 $-628K

Balance Statement

Period Cash & Short-term Total Assets Total Liabilities Total Equity
Q3-2025 $2.722M ▼ $2.145M ▼ $9.703M ▼ $-7.559M ▼
Q2-2025 $4.096M ▲ $6.488M ▲ $10.462M ▲ $-3.974M ▼
Q1-2025 $872.96K ▼ $988.65K ▼ $1.077M ▲ $-88.329K ▼
Q4-2024 $1.838M ▲ $1.956M ▲ $942.759K ▲ $1.013M ▲
Q3-2024 $1.056M $1.508M $789.32K $719.007K

Cash Flow Statement

Period Net Income Cash From Operations Cash From Investing Cash From Financing Net Change Free Cash Flow
Q3-2025 $-4.487M ▲ $-1.495M ▼ $943.18K $4.305M ▼ $1.849M ▼ $-1.495M ▼
Q2-2025 $-5.058M ▼ $-1.167M ▼ $943.18K ▲ $4.423M ▲ $4.082M ▲ $-1.167M ▼
Q1-2025 $-1.44M ▲ $-1.068M ▼ $0 $102.519K ▼ $-965.509K ▼ $-1.068M ▼
Q4-2024 $-1.554M ▼ $-819.791K ▼ $0 $1.602M ▲ $782.664K ▲ $-819.791K ▼
Q3-2024 $-640.785K $-185.661K $0 $316.959K $131.209K $-185.661K

Five-Year Company Overview

Income Statement

Income Statement PTIX has been a classic early‑stage biotech story on the income statement: no commercial revenue at all over the past several years and recurring net losses every year. Earnings per share have stayed negative and somewhat volatile, which usually reflects ongoing R&D and corporate costs being spread over a changing share count. The operating loss recently ticked up slightly, but overall the pattern is consistent with a pre‑revenue company still in the development phase, not yet in a position to self‑fund operations from product sales.

Balance Sheet

Balance Sheet The balance sheet looks very thin, with only a small base of assets and equity reported and no financial debt in the disclosed period. This suggests a company running lean, likely relying on equity raises rather than borrowing. Multiple reverse stock splits over the years hint at ongoing pressure on the share price and repeated recapitalizations. Overall, the historical balance sheet signals limited financial cushion and a dependence on external financing to keep the pipeline moving.

Cash Flow

Cash Flow Reported cash flow data are essentially flat in the disclosure, but the business model implies cash outflow from operations every year to pay for research, trials, and overhead, with no offsetting inflow from product sales. Capital spending appears minimal, which is typical for a virtual or asset‑light biotech. In practice, cash needs are likely being covered by issuing new shares or other financing rather than by internal cash generation, underscoring sensitivity to capital markets conditions.

Competitive Edge

Competitive Edge After the merger with Phytanix Bio, the combined company (now operating as Phytanix, Inc.) has a stronger strategic position than legacy PTIX alone. It now fields a broader central nervous system and metabolic pipeline, combining a clinical‑stage peptide program with several preclinical cannabinoid and related compounds. The team brings experience from prior cannabinoid drug successes, plus an expanded patent estate. That said, the company still competes in a crowded and high‑risk neuro and metabolic space, going up against much larger, better‑funded players. Its edge rests mainly on differentiated science, specialized know‑how, and intellectual property rather than on scale or commercial presence.

Innovation and R&D

Innovation and R&D Innovation is the core asset here. The lead program, PT00114, targets stress‑related and mood disorders through a novel mechanism that aims to modulate the body’s stress response rather than just treating symptoms. This first‑in‑class angle, if borne out in trials, could be highly differentiating. The merger adds a second innovation pillar: cannabinoid‑based and modified stilbenoid compounds, including a potassium channel modulator and other candidates for CNS, epilepsy, and metabolic disorders. The company is still mostly preclinical, with only one program in early human testing, so scientific promise is high but clinical risk remains substantial. Near‑term value drivers hinge on early‑stage trial readouts and how quickly additional assets can be advanced toward the clinic.

Summary

Historically, PTIX was a financially weak, pre‑revenue biotech with persistent losses, a very small asset base, no debt, and reliance on equity markets to fund operations, as reflected in repeated reverse stock splits. The merger with Phytanix Bio significantly improves the strategic story—broadening the pipeline, deepening expertise in both peptide and cannabinoid science, and strengthening the patent position. However, the company remains early‑stage, with no approved products, limited financial resources, and heavy dependence on successful trial outcomes and continued access to capital. The next few years are likely to be defined by clinical milestones for PT00114, progress on preclinical assets, and the company’s ability to manage cash and integration risk while pushing an ambitious R&D agenda forward.

NEWS

November 27, 2025 · 3:45 AM UTC

Protagenic Therapeutics Announces Receipt of Nasdaq Non-Compliance Notice

Read more

November 13, 2025 · 8:22 AM UTC

Protagenic Therapeutics Announces Completion of Enrollment and Dosing in Phase 1 MAD Study

Read more